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Preeclampsia, a heterogeneous, multisystem disorder de-fined by the new onset of hypertension and proteinuria or 
evidence of end-organ dysfunction after 20 weeks of gestation 
affects 2 to 5% of pregnancies worldwide.1,2 Preeclampsia is 
associated with a high risk of iatrogenic preterm birth, small 
for gestational age (SGA) infant, placental abruption, and per-
inatal mortality, along with significant maternal morbidity and 
mortality.3
Although hypertension and proteinuria are hallmarks of 
the disease, they have poor predictive value for the develop-
ment of adverse outcomes.4 In addition, the initial clinical pre-
sentation is heterogeneous and current clinical tools applied 
to women who present with clinical suspicion of the disease 
do not allow accurate prediction of the development of pre-
eclampsia even in the short term; this inability to effectively 
rule in or rule out the condition in those at risk means some 
cases are missed,5 whereas many women are unnecessarily 
admitted for monitoring or followed up intensively.
Recently, angiogenic factors (specifically sFlt-1 [soluble 
fms-like tyrosine kinase 1] and/or PlGF [placental growth 
factor]) have been suggested as good candidate biomark-
ers for the prediction of preeclampsia occurring in the short 
term. The largest study conducted to date analyzed the per-
formance of the sFlt-1/PlGF ratio in women who presented 
with suspected preeclampsia.6 The study showed that a ratio 
≤38 conferred a negative predictive value (NPV) of 99.3% 
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(95% CI, 97.9–99.9) for developing preeclampsia within 
7 days, whereas a ratio >38 conferred a positive predictive 
value (PPV) of 36.7% (95% CI, 28.4–45.7) for developing 
preeclampsia within 4 weeks.6
Several authors suggested that implementation of sFlt-1/PlGF 
into clinical practice may be of benefit by reducing unnecessary 
admissions for those at low risk of developing the disease in the 
short term and by more targeted increase in surveillance for those 
at high risk.7–10 Additionally, given its good correlation with out-
comes,11–14 it has been suggested that it could be valuable in guiding 
management in women with preeclampsia, such as optimization 
of timing of delivery or timing of corticosteroid administration. 
Collectively this could allow better resource allocation by reducing 
costs in low-risk women, and potentially improve outcomes in both 
low- and high-risk women.8 However, existing studies are either 
observational or retrospective and meaning that economic analyses 
and recommendations for clinical use have limitations.15
To address these shortcomings, we designed this random-
ized clinical trial to assess whether the sFlt-1/PlGF ratio, used 
in combination with current clinical guidelines as used in real-
life practice, could reduce the number of women admitted due 
to a suspicion of preeclampsia and to assess the real-world 
performance and clinical utility of this test in its ability to de-
tect preeclampsia in daily clinical practice.
Methods
Additional information on the data, materials, or analytic methods 
that support the findings of this study are available from the corre-
sponding author on reasonable request.
Trial Design
INSPIRE (Interventional Study Evaluating the Short-Term Prediction 
of Preeclampsia / Eclampsia In Pregnant Women With Suspected 
Preeclampsia) was a prospective interventional randomized, parallel-
group, controlled trial conducted in the United Kingdom.
We used a 1:1 ratio for randomization. Participants were individ-
ually randomized to either standard clinical management or standard 
clinical management + sFlt-1/PlGF ratio result. The allocation was 
determined by the laboratory team using 1:1 randomization using a 
computer-based system. The allocation was not known to the clinical 
teams assessing the women.
Participants
Eligible participants were pregnant women (18 years old or older), 
between 24+0 and 37+0 weeks of gestation with a clinical suspicion 
of preeclampsia. This was judged according to the following: new 
onset elevated blood pressure6 or worsening of preexisting hyperten-
sion or new onset proteinuria (any protein in the urine >trace on dip-
stick) or worsening of preexisting proteinuria or new onset headache, 
visual disturbance, edema or right upper quadrant pain, or any other 
clinical suspicion of preeclampsia.
Exclusion criteria were preexisting diagnosed preeclampsia/ec-
lampsia or hemolysis, elevated liver enzyme levels, and low platelet 
counts syndrome, multiple pregnancy, inability to provide informed 
consent/unwillingness to participate or significant disease (ie, cancer) or 
disorder (ie, significant mental health problems), which in the opinion of 
the investigator might either put the participants at risk or influence the 
result of the study or the participant’s ability to participate in the study.
Settings and Locations Where Data Was Collected
The study took place at the John Radcliffe Hospital (Oxford University 
Hospitals NHS Foundation Trust) in Oxford, United Kingdom from 
June 2015 to April 2017. The John Radcliffe is a tertiary referral 
center with a preeclampsia prevalence of 2.9%.
Standard Clinical Management of Suspected 
Preeclampsia
Management of suspected preeclampsia involved initial assessment 
of blood pressure, proteinuria (first by urine dipstick and then by urine 
protein:creatinine ratio if dipstick was positive), urine microscopy 
and culture, baseline blood tests (full blood count, urea and electro-
lytes, liver function tests, and clotting), as well as physical examina-
tion and cardiotocography. Blood pressure was managed according 
to the National Institute for Health and Care Excellence guidelines.16 
Decisions to admit were made by the attending doctor (either alone 
or after discussion with a senior colleague) and depended on clinical 
condition or concerns. Ultrasonographic assessment of the fetus was 
usually performed on those patients who were admitted.
Intervention
Women who presented with signs or symptoms of preeclampsia were 
approached to participate in the study. After informed consent, they had 
clinical assessment and standard clinical management blood taken as well 
as an additional sample for sFlt-1/PlGF. Blood samples were processed 
in the central laboratory, and turn-around time was 60 minutes. Once the 
sample was received, women were randomized by the laboratory team to 
either nonreveal (comparator; standard clinical management) or reveal 
(intervention; standard clinical management + sFlt-1/PlGF ratio result) 
trial arms and the clinical team informed of the allocation.
In the reveal (intervention) arm, the sFlt-1/PlGF results were availa-
ble to the clinicians alongside the other requested blood samples. In the 
nonreveal (comparator) arm, the sFlt-1/PlGF results were not available 
until trial completion, and patients were managed according to standard 
clinical management, without knowledge of sFlt-1/PlGF ratio. The same 
clinical team attended women from the reveal and nonreveal trial arms.
In the reveal arm, sFlt-1/PlGF ratio was incorporated into the clin-
ical decision framework with a ratio of ≤38 considered to confer low 
risk of developing preeclampsia within 7 days and a ratio >38 deemed 
elevated risk.6 The clinical algorithm for the reveal group advised dis-
charge of women with ratio ≤38 unless deemed necessary by the cli-
nician due to concerning clinical features. For women with ratio >38, 
a low threshold for admission or increased surveillance was advised.
Admission was defined as any admission arising within 24 hours, 
driven by clinical assessment (+ sFlt-1/PlGF ratio in the reveal group 
only) at the time of recruitment. (S1 Appendix in the online-only Data 
Supplement). Importantly, the decision-making in the reveal group was 
not based only on the ratio but on the consideration of the ratio in con-
junction with assessment of the clinical picture (ie, if the attending cli-
nician thought admission was warranted, the patient was admitted). 
Although pathways for the intervention and control arms were provided 
to clinicians, the final management decision, based on either subjective or 
structured risk assessment, as well as test results, was at the clinician’s dis-
cretion, reflecting a pragmatic approach to more reliably assess real-world 
effectiveness. Continuous training and education about the ratio and its 
clinical interpretation were given before and during the trial. Knowledge 
of the ratio was used only as an indication for admission and follow-up 
not for delivery, which was performed according to current clinical guide-
lines. Research staff recorded, but did not intervene in, clinical decisions.
sFlt-1/PlGF Test
Serum samples were sent from the clinical area to the laboratory and 
were centrifuged within 1 hour of sample collection. sFlt-1 and PLGF 
were measured using fully automated methods on the Roche e411 an-
alyzer (Roche Diagnostics Limited, Burgess Hill, United Kingdom). 
Method reproducibility, assessed as interassay percent coefficient of 
variation, for sFlt-1 was 5.1% at 102 pg/mL and 2.8% at 1043 pg/
mL and for PLGF was 3.0% at 106 pg/mL and 2.9% at 1069 pg/mL.
Outcomes
A Priori Defined Outcomes
Primary Outcome
The primary outcome was preeclampsia-related inpatient admission 
within 24 hours of the test, within 7 days, or by delivery. Preeclampsia-
related inpatient admission was defined as an admission driven by 
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suspicion of preeclampsia defined as above, where preeclampsia has 
been recorded as a differential diagnosis and where ongoing blood pres-
sure monitoring, assessment of proteinuria, and preeclampsia blood 
samples have been requested. Patients who were admitted without these 
(eg, after premature rupture of membranes or threatened preterm labor) 
were not deemed to have had a preeclampsia-related admission. This 
was defined after case report form review by experienced clinicians who 
were blinded to the trial arm, sFlt-1/PlGF result, and clinical outcome. 
If 3 independent assessors could not unanimously agree, an external ar-
biter (A.T. Papageorghiou) made the final decision—in 4 cases.
Secondary Outcomes
Secondary outcomes were incidence of preeclampsia within 7 days 
and by the time of delivery; birth weight; Special Care Baby Unit 
(SCBU) admission; Appearance, Pulse, Grimace, Activity, and 
Respiration (APGAR) score at delivery; platelet count, renal, and 
hepatic function measured using blood tests at time of first clinical 
assessment (ie, study enrollment/baseline) and time of delivery.
The diagnosis of preeclampsia was made according to the follow-
ing criteria: diastolic BP ≥90 mm Hg or systolic blood pressure ≥140 
mm Hg together with proteinuria (urine protein/creatinine ≥30 mg/
mmol) or serum creatinine >97 μmol/L, elevated liver transaminases to 
twice the normal concentration or platelets <100 000/dL. Superimposed 
preeclampsia was defined as an elevation in diastolic BP of >15 mm Hg 
or systolic blood pressure >30 mm Hg, together with (urine protein/cre-
atinine ≥30 mg/mmol), or serum creatinine >97 μmol/L, elevated liver 
transaminases to twice the normal concentration, platelets<100 000/dL.
SGA was defined as birth weight <10th centile adjusted for new-
born sex (Viewpoint software, GE Healthcare, United Kingdom).
Outcomes were prospectively extracted from the electronic re-
cords, and case notes from the time of birth and with outcome asses-
sors blinded to the sFlt-1/PlGF result. In instances where preeclampsia 
was not reported before discharge, research staff made a 6-week phone 
call after delivery and searched online data portals and electronic pa-
tient records to determine if postnatal readmissions and additional rel-
evant information existed that had not been reported previously.
Post Hoc Changes From Initial Study Protocol. The predefined defi-
nition of preeclampsia in the study was updated before the study started 
in line with the statement from the International Society for the Study 
of Hypertension in Pregnancy2 and American College of Obstetricians 
and Gynecologists.1 The new definition does not require the presence 
of proteinuria; therefore, patients with hypertension and no proteinuria 
but signs of end-organ damage were classified as preeclampsia.1,2
Post Hoc Analyses. In addition, we subsequently analyzed the following:
1. Time (from enrollment) to preeclampsia diagnosis.
2. Sensitivity, specificity, NPV, and PPV for the sFlt-1/PlGF ratio.
Sample Size and Statistical Analyses
We estimated that we would need to enroll 366 women (183 in each 
arm) to detect a 15% reduction in admission rates between trial arms 
with a power of 80%, a 2-sided significance level of 5% and 1:1 ran-
domization, allowing a 5% loss to follow-up.
Analysis was undertaken on an intention-to-treat basis, and no in-
terim analyses were performed. Characteristics of study participants 
were summarized using simple proportions and medians with inter-
quartile ranges (IQR) or means with SD stratified by trial arm.
The primary outcome was reported as risk ratio and risk differ-
ence. The secondary outcomes were reported as difference in pro-
portions between groups using the χ2 test or differences in means 
or medians using t test or Wilcoxon, respectively, depending on the 
variables. Comparison between trial arms was performed using a 
difference-in-differences statistical test using ANCOVA or logistic 
regression for categorical variables. Significance was set at 0.05, and 
all the analyses were 2-sided. All statistical analysis (a priori and post 
hoc) was performed using STATA version 15.1 (College Station, TX).
Randomization
We used a computer-based system to randomize patients with a pre-
determined ratio of 1:1. The person enrolling the participant in the 
clinical team did not know in advance which trial arm the next patient 
would be allocated to.
Blinding
Women and the clinical team responsible for the enrolled women 
were aware of the allocated trial arm (comparator versus interven-
tion). Women and the clinical team caring for the reveal trial arm (in-
tervention) were aware of the sFlt-1/PlGF result. Outcome assessors 
and data analysts were kept blind to sFlt-1/PlGF result and trial arm. 
sFlt-1/PlGF results from the nonreveal trial arm were only released at 
the end of the study.
Role of the Funding Source
The trial was funded by Roche Diagnostics GMBH and Roche 
Diagnostics Ltd. The University of Oxford sponsored the study. The 
study protocol was designed by the investigators and reviewed by the 
funder. The funder had no role in data collection or data analysis or 
final article approval. The authors analyzed and interpreted the data 
and wrote the article. All authors were independent of the funders.
It was approved by the Research Ethics Committee, National 
Research Ethics Committee South Central–Oxford B (Research 
Ethics Committee number 15/SC/0126).
Results
Baseline Characteristics of Trial Population
Between June 2015 and April 2017, a total of 381 women 
with suspected preeclampsia presenting at the John Radcliffe 
Hospital, Oxford, were enrolled. Eleven women were with-
drawn (Figure 1). Analysis, therefore, included 370 women with 
184 in the nonreveal and 186 in the reveal groups. The baseline 
clinical characteristics of each group are presented in Table 1. 
There were no significant differences between the characteris-
tics of nonreveal and reveal and trial arms except for body mass 
index, which was driven by 3 outliers in the reveal group.
Primary Outcome
Admissions
There was no difference in preeclampsia-related admissions 
within 24 hours of the test between trial arms. Sixty patients 
were admitted in the intervention group (reveal) and 48 in the 
comparator group (nonreveal; risk ratio, 1.24 [0.89–1.70]; 
Table 2). Similarly, there was no difference in preeclampsia 
related admissions within 7 days (risk ratio, 1.06 [0.81–1.39]) 
or by delivery (risk ratio, 0.93 [0.82–1.06]). No differences 
were seen in admissions for any nonpreeclampsia-related 
reason (risk ratio, 1.22 [0.93–1.62]; Table S2).
Secondary Outcomes
Preeclampsia Within 7 Days of the Test
The overall preeclampsia rate for the entire trial population was 
23% (n=85/370). There was no significant difference in the in-
cidence of preeclampsia between the trial arms (P=0.291). 
Significantly more women who developed preeclampsia within 7 
days were admitted in the reveal trial arm than the nonreveal trial 
arm (P=0.038; Table 3). In the reveal arm, 100% (n=24/24) of 
women who developed preeclampsia within 7 days were admit-
ted (PPV, 40.0% [95% CI, 27.6–53.5]; sensitivity, 100% [95% 
CI, 85.8–100]; specificity, 77.8% [95% CI, 70.6–83.9]). This is in 
contrast with the nonreveal trial arm where 83% (n=15/18) were 
admitted (PPV, 31.3% [5% CI, 18.7–46.3], sensitivity; 83.3% 
[95% CI, 58.6–96.4], specificity 80.1% [95% CI, 73.2–85.9]). 
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Three patients who were discharged home in the nonreveal arm 
developed preeclampsia within 7 days (Table 3). A full break-
down of outcomes trial arms and between admitted and nonad-
mitted is presented in Tables S3A and S3B, respectively.
Birthweight
In both trial arms, babies of women that were admitted were 
smaller than those that were not admitted (Table 4). In the nonre-
veal arm, the median birthweight in admitted women was 3070g 
(IQR, 2408–3455 g), whereas it was 3305 g (IQR, 2820–3753 g) 
in nonadmitted women (difference, 240 g; P=0.007). In the reveal 
trial arm, this difference was significantly more pronounced, with 
a difference of 620 g and respective birthweight of 2818 g (IQR, 
2363–3203 g) and 3433 g (IQR, 3045–3780 g; P=0.000; Table 4).
Small for Gestational Age
The percentage of SGA infants in nonreveal trial arm was 
22.9% (n=11/48) in the admitted and 14.7% (n=20/136) in 
the non admitted women (P=0.19). In contrast, there was a 
significant difference in the reveal trial arm, with the rate of 
SGA being 26.7% (16/60) in the admitted women and 11.9% 
(15/126) in the nonadmitted women (P=0.012; Table 4).
SCBU Admission
SCBU attendance showed a similar pattern to SGA. (Table 2A). 
In the nonreveal trial arm, there was a similar rate of SCBU at-
tendance between admitted (16.7%) and non admitted women 
(14.7%; P=0.745). This is in contrast with the reveal trial arm 
where there was a significant difference among infants of admit-
ted and nonadmitted women. Infants of admitted women had a 
higher rate of SCBU attendance than infants from nonadmitted 
women (26.7% versus 14.3% respectively, P=0.041; Table 4).
APGAR Score at First Minute
There was no difference between admitted (9 [IQR, 8–10]) 
and nonadmitted (9 [IQR, 8–10]) women in the nonreveal trial 
arm (P=0.938), but there was a significant difference in the 
reveal trial arm (9 [IQR, 8–9]) in infants of admitted and (9 
[IQR, 8–10]) nonadmitted women (P=0.000; Table 4).
Maternal Blood Tests
In the nonreveal group, there was no difference between 
admitted versus nonadmitted patients for platelets, creati-
nine, ALT (alanine aminotransferase), and uric acid at time 
of delivery. In contrast, in the reveal group, there were signif-
icantly higher levels of creatinine, uric acid, and significantly 
lower levels of platelets between admitted and nonadmitted 
women (Table 4).
The same pattern was seen when analyzing maternal 
blood samples at presentation alone or change per day, with 
no difference between admitted and nonadmitted in nonreveal 
trial arm and a significant difference in the reveal trial arm 
(data not shown).
Trial Arm Comparison
Trial arm comparison revealed significant differences in the 
segregation of at-risk patients (admitted versus nonadmitted). 
This showed that use of the ratio was significantly more effec-
tive at discriminating and directing admission of patients at 
risk of preeclampsia within 7 days, lower birth weight, lower 
APGAR scores, SGA babies, and worse maternal biochemical 
profiles, as well as time of delivery compared with standard 
clinical management (Table 4).
Post Hoc Analyses
Time to Preeclampsia Diagnosis in Both Trial Arms
To assess if knowledge of the ratio would allow us to make 
the diagnosis of preeclampsia earlier, we assessed the time 
to preeclampsia diagnosis in both trial arms (Figure 2 and 
Table S4). The median time to diagnosis in nonreveal was 
9.5 days (IQR, 0–32) compared with 7 days (IQR, 0–29) 
381 patients were enrolled
7 were excluded
    4 sample not processed
    3 not elegible
186 were assigned to Non-Reveal group 188 were assigned to Reveal group
184 were included in the analysis 186 were included in the analysis
374 underwent randomization
2 were lost to follow-up 2 were lost to follow-up
Figure 1. Recruitment, randomization, and follow-up.
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in the reveal arm (P=0.6387). The Kaplan-Meier analysis 
consistently showed a trend towards earlier diagnosis in 
the reveal arm (Figure 2). Preeclampsia severity and addi-
tional maternal adverse outcomes are presented in Tables 
S5A and S5B.
Sensitivity Specificity, NPV, PPV in Both Trial Arms
In the nonreveal arm, the sensitivity in predicting the devel-
opment of preeclampsia within 7 days was 83.3% (95% CI, 
58.6–96.4) for a specificity of 80.1% (95% CI, 73.2–85.9); 
this was in contrast to the reveal arm, which resulted in a 
sensitivity of 100% (95% CI, 85.8–100) for a specificity of 
77.8% (95% CI, 70.6–83.9). The sFlt-1/PlGF ratio alone gave 
a better sensitivity than the nonreveal arm at 95.8% (95% CI, 
78.9–99.9). This increased sensitivity was achieved without 
significant loss of specificity (Figure 3).
The PPV for the development of preeclampsia within 7 
days in the nonreveal arm was 31.3% (95% CI, 18.7–46.3) 
compared with 40% (95% CI, 27.6–53.5%) in the reveal arm. 
The PPV for the ratio alone was 41.1% (95% CI, 28.1–55.0). 
The NPV for nonreveal was 97.8% (95% CI, 93.7–99.5) re-
flecting the 3 patients sent home in this arm. The NPV for the 
reveal arm was 100% (95% CI, 97.1–100) and for the ratio 
alone was 99.2% (95% CI, 95.8–100; Figure 3).
Discussion
At present, the identification of those patients with suspected 
preeclampsia who warrant admission can be challenging, 
leading to either unnecessary admissions or missed diag-
noses. This is mostly because of inappropriate allocation to 
high-risk and low-risk groups with standard clinical tools. In 
this pragmatic trial, women presenting with suspected pre-
eclampsia were randomized to management by sFlt-1/PlGF 
ratio test in conjunction with standard clinical care versus 
standard clinical care alone to assess the value of this test 
on clinical management and admission decisions. There was 
no difference in the overall number of admissions between 
the 2 arms. However, using the sFlt-1/PlGF ratio permitted a 
more accurate admission of high-risk patients and discharge 
of low-risk patients without changing the overall admission 
rate. This is supported by the admission of 100% of pree-
clampsia patients. In addition, the admitted women were 
more likely to have elevated creatinine and urate and lower 
platelets, whereas their newborns had lower birth weight and 
Table 1. Baseline Characteristics of Trial Participants
Patient Characteristics Nonreveal Arm (n=184) Reveal Arm (n=186)
Statistical Significance; P 
Value
GA at recruitment, week, median (IQR) 34.4 (31.4–35.7) 34.3 (31.3–36.0) 0.903
Maternal age at recruitment, y, median (IQR) 31.1 (26.7–34.7) 30.9 (27.4–35.8) 0.473
BMI, median (IQR) 26.7 (23.1–31.7) 28.3 (24.3–32.4) 0.045
Parity n (%)   0.351
  Nulliparous 94 (51.1%) 86 (46.2%)  
  Multiparous 90 (48.9%) 100 (53.8%)  
Smoking status n (%)   0.398
  Current smoker 16 (8.7%) 17 (9.1%)  
  Never smoker 118 (64.1%) 107 (57.5%)  
  Previous smoker 50 (27.12%) 62 (33.3%)  
Ethnicity n (%)   0.794
  White 166 (90.2%) 166 (89.2%)  
  Other 15 (8.2%) 18 (9.7%)  
  Not recorded 3 (1.6%) 2 (1.1%)  
Highest systolic BP at presentation, median (IQR) 132 (120–146) 131 (120–148) 0.826
Highest diastolic BP at presentation, median (IQR) 80 (71–92) 84 (70–93) 0.900
P≤0.05 was considered statistically significant. BMI was calculated as the weight (kilograms) divided by the square of the height (meters); ethnic group 
was reported by the participants. BMI indicates body mass index; BP, blood pressure; GA, gestational age; and IQR, interquartile range.
Table 2. Primary Outcome
Admissions for Suspected PE
Trial Arm Statistics
Nonreveal (n=184) Reveal (n=186) Risk Ratio (95% CI) Risk Difference (95% CI)
Within 24 h of the test, n (%) 48 (48/184=26.1%) 60 (60/186=32.3%) 1.24 (0.89 to 1.70) 0.06 (−0.03 to 0.15)
Within 7 days of the test, n (%) 65 (65/184=35%) 70 (70/186=37.6%) 1.06 (0.1 to 1.39) 0.02 (−0.07 to 0.12)
Until delivery, n (%) 134 (134/184=72.8%) 126 (126/186=67%) 0.93 (0.82 to 1.06) −0.05 (−0.14 to 0.04)
Admissions for suspected PE within 24 h of the test, 1 wk and until delivery. Admissions were calculated as cumulative admissions divided by the total number of 
patients. PE indicates preeclampsia.
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APGAR scores higher SCBU admission rates: all indicators 
of a higher risk group.
We hypothesized that use of the sFlt-1/PlGF ratio would 
reduce overall hospitalization—a proxy for a clinical concern 
that the patient would develop preeclampsia or preeclampsia-
related problems; however, this was not found. Nevertheless, 
use of the test increased the proportion of high-risk patients 
admitted, without influencing the admission rate. The clear-
est example is in the correct identification of women with 
preeclampsia in the reveal arm where use of the ratio in 
combination with standard clinical management identified 
100% of the patients, whereas standard clinical management 
(nonreveal), by the same clinical team, identified 83%. This 
translated to 3 patients being sent home who subsequently de-
veloped preeclampsia, and, therefore, remained at risk of ad-
verse maternal and infant outcomes.17,18
In addition to preeclampsia, the use of the test allowed us 
to identify women at higher risk of other adverse outcomes, 
Table 3. Proportion of Preeclampsia Patients Admitted for Nonreveal and Reveal Trial Arms
PE Within 7 Days PE Until Delivery
Admission Status Nonreveal; n=18 Reveal; n=24 Statistics Nonreveal; n=38 Reveal; n=47 Statistics
Admitted 15 24 … 20 31 …
Nonadmitted 3 0 … 18 16 …
Admitted proportion (15/18) 83% (24/24) 100% P=0.038 (20/38) 52.6% (31/47) 65.9% P=0.242
PE indicates preeclampsia.
Table 4. Secondary Outcomes of Reveal and Nonreveal Trial Arms
Outcomes
Nonreveal 
Trial Arm
Reveal 
Trial Arm
P Value 
(*-† vs ‡-§)
Total; 
n=184
Admitted*; 
n=48
Nonadmitted†; 
n=136
P Value; 
Admitted vs 
Nonadmitted 
(*-†)
Total; 
n=186
Admitted‡; 
n=60
Nonadmitted§; 
n=126
P Value; 
Admitted vs 
Nonadmitted 
(‡-§)
PE within 7 d 18/184  
(9.7%)
15/48  
(34.8%)
3/136  
(2.2%)
0.000 24/186  
(12.9%)
24/60  
(40%)
0 /126  
(0%)
0.000 0.000
Total PE 38/184  
(20.6%)
20/48  
(41.6%)
18/136  
(13.2%)
0.000 47/186  
(25.2%)
31/60  
(51.6%)
16/126  
(12.6%)
0.000 0.000
Birthweight, median 
(IQR)
3268  
(2723–3700)
3070  
(2408–3455)
3305  
(2820–3753)
0.008 3235  
(2780–3685)
2818  
(2363–3203)
3433  
(3045 3780)
0.000 0.000
APGAR first minute, 
median (IQR)
9 (8–10) 9 (8–10)1 9 (8–10) 0.938 0 (8–10) 9 (8–9)2 9 (8–10)3 0.000 0.001
SCBU admissions, 
n (%)
28/184  
(15.2%)
8/48  
(16.7%)
20/136  
(14.7%)
0.745 34/186 
(18.3%)
16/60 
(26.7%)
18/126  
(14.3%)
0.041 0.081
SGA, n (%) 31/184  
(16.8%)
11/48  
(22.9%)
20/136  
(14.7%)
0.191 31/186  
(16.7%)
16/60  
(26.7%)
15/126  
(11.9%)
0.012 0.007
Maternal Cr, median 
(IQR; at delivery)
58  
(49–68)
57  
(49–66)4
58  
(49–70)5
0.689 58.5  
(51–67)
62  
(54–72)6
57  
(48–63)7
0.002 0.030
Maternal urates 
median (IQR; at 
delivery)
349.5  
(303–409)
374  
(311.5–433)8
345  
(294.5–401.5)9
0.209 348  
(277–426)
393  
(316–453)10
315  
(265–393)11
0.002 0.003
Maternal Alt, median 
(IQR; at delivery)
14.5  
(10–27)
16  
(11–29)12
14  
(10–24)13
0.525 15  
(11–27)
17  
(12–33)14
14.5  
(10.5–23.5)15
0.153 0.998
Maternal Plt, median 
(IQR; at delivery)
219.5  
(174–274)
224  
(200–273)16
214  
(173–277)17
0.422 220  
(192–263)
204  
(171–259)18
233  
(199–269)19
0.030 0.360
GA at delivery 
weeks, median (IQR)
38.1  
(37.1–39.3)
37.6  
(36.3–38.7)
38.5  
(37.4–39.4)
0.000 38.4  
(37.3–39.6)
37.2  
(36.1–38.2)
39.0  
(37.9–39.9)
0.000 0.000
Proportion test, Wilcoxon, and Student t test were performed. Difference between trial arms was calculated using a difference-in-differences statistical test using 
ANCOVA or logistic regression for categorical variables. P≤0.5 was considered significant.1–3 Missing data for 1;2 and 1 patients respectively.4,7,8,11,12,15,16,19 Missing data 
for 1 patient.4–15 Sample deemed not necessary by clinical team for 4;39;1;38;8;53;1;48;4;43;1 and 41 patients, respectively.17–19 Sample deemed not necessary by 
clinical team for 13;1 and 14 patients, respectively. Alt indicates alanine aminotransferase; APGAR, Appearance, Pulse, Grimace, Activity, and Respiration; Cr, Creatinine; 
GA, gestational age; IQR, interquartile range; PE, preeclampsia; Plt, platelets; SCBU, special care baby unit; and SGA, small for gestational age.
*
†
‡
§
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including lower birthweight infants, SGA infants, increased 
SCBU admissions, and lower APGAR scores. This suggests 
that use of the ratio with clinical practice might have broader 
clinical utility not only for predicting preeclampsia but also 
for related adverse outcomes, as has been suggested by obser-
vational studies.11–13 Alongside these impacts, use of the ratio 
also allowed safe discharge of patients at extremely low risk 
of preeclampsia. In this study, 126 patients with an initial sus-
picion of preeclampsia had a ratio ≤38 and were not admit-
ted; of these, none developed preeclampsia within 7 days. In 
effect, use of the test allowed admission of the right patients.
Post hoc analysis showed a nonsignificant trend towards a 
more rapid diagnosis of preeclampsia in the reveal arm. This 
may be of clinical value in that it suggests that the diagnosis 
is made more quickly with knowledge of the ratio. This may 
be either because of increased surveillance or admission of 
high-risk patients and may ultimately have an impact on in-
fant outcomes. Larger independent studies are warranted to 
confirm or refute this hypothesis.
When comparing the nonreveal trial arm with reveal for ad-
mission of women who developed preeclampsia within 7 days, 
we saw an increase in sensitivity from 83.3% to 100% with 
similar specificity (80.1% versus 77.8%). The PPV of the reveal 
arm was 40.0% compared with 31% for the nonreveal arm. The 
NPV for the reveal arm was 100% compared with 97.8% for 
the nonreveal arm (reflecting the 3 patients sent home). When 
comparing the sensitivity of the ratio alone (95.8% [95% CI, 
78.9–99.9]) it outperformed standard practice (nonreveal) but 
was not as sensitive as the ratio in combination with clinical 
practice (reveal). Its specificity was comparable (79.5% [95% 
CI, 72.4–85.5]) with both standard practice and use of the ratio 
together with standard practice. Its NPV was reassuringly sim-
ilar (99.2% [95.8–100]) to that reported in previous observa-
tional studies.6 These data suggest use of the ratio together with 
standard clinical practice provides better performance than ei-
ther the ratio alone or standard clinical practice alone.
The limitations of this study include the fact that it was 
confined to a single center, which might limit the generaliza-
bility of the findings; it is possible that admission rates differ 
in other units, although the ability of sFlt-1/PlGF to distinguish 
women more likely to develop preeclampsia should not be af-
fected by this. The unit is a tertiary referral center; test perfor-
mance, which included clinical assessment, may differ in a less 
experienced unit where we hypothesize that use of the ratio 
would be even more beneficial. It has not escaped our attention 
that the PPV of the test alone outperformed standard clinical 
practice. This might be beneficial in resource-poor environ-
ments where there is poorer recognition of the disease.19
This is the first randomized clinical trial assessing the use 
of angiogenic biomarkers sFlt-1 and PlGF in women with 
suspected preeclampsia. It provides real-world evidence for 
the implementation of sFlt-1/PlGF ratio in clinical practice. 
We observed no change in admission rates, but the results of 
this study clearly show that the sFlt-1/PlGF ratio in combina-
tion with standard clinical practice both identifies and leads 
to correct admission of women with increased risks of pre-
eclampsia and worse biochemical profiles, infants with low 
birth weight, SGA, low APGAR scores, and increased SCBU 
admission. This ability lends itself to now asking whether the 
test could be used to mitigate some of these outcomes, in-
cluding influencing the timing of birth. Larger studies will be 
needed to elucidate this.
In summary, use of the sFlt-1/PlGF ratio improved clinical 
precision without affecting admission rates.
0.50
0.75
1.00
0 20 40 60 80 100
analysis time
Non-reveal Reveal
Figure 2. Kaplan-Meier survival estimate for time to preeclampsia 
development, by trial arm.
Non-reveal
(SCM only)
PE in 7 days
Reveal
(SCM+ratio)
PE in 7 days
admission Yes No admission Yes No
Yes 15 33 48 Yes 24 36 60
No 3 133 136 No 0 126 126
18 166 184 24 162 186
Reveal 
PE in 7 days
Yes No
>38 23 33 56
<38 1 129 130
24 162 186
Non-reveal
SCM only
Reveal 
SCM+ratio
Reveal
Ratio only
Sensitivity: 83.3% (58.6-96.4) 100% (85.8-100) 95.8 (78.9 – 99.9)
Specificity: 80.1 (73.2-85.9) 77.8% (70.6-83.9) 79.6 (72.6 – 85.5)
PPV: 31.3% (18.7-46.3) 40.0% (27.6-53.5) 41.1  (28.1 – 55.0)
NPV: 97.8% (93.7-99.5) 100% (97.1-100) 99.2  (95.8 – 100)
(ratio only)
“admission - No”
“admission - Yes”
ratio
Figure 3. Post hoc analysis. Negative predictive value (NPV), positive predictive value (PPV), sensitivity, and specificity of standard clinical management (SCM) 
with and without sFlt-1 (soluble fms-like tyrosine kinase 1)/PlGF (placental growth factor) ratio for the prediction of preeclampsia (PE) diagnosis within 7 d.
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Perspectives
The management of suspected is clinically complex, princi-
pally because of the poor clinical tools currently available. 
The measurement of angiogenic factors (sFlt-1 and PlGF) has 
shown significant promise in improving this situation. Here, 
we present the first clinical trial on the use of sFlt-1/PlGF 
ratio in patients with suspected preeclampsia and showed that 
use of the ratio in conjunction with standard clinical practice 
significantly improves clinical precision without changing ad-
mission rates.
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What Is New?
•	This is the first clinical trial to use sFlt-1 (soluble fms-like tyrosine 
kinase 1)/PlGF (placental growth factor) test in triage of women with 
preeclampsia.
What Is Relevant?
•	Use of the test allowed the correct triage and hospitalization of patients 
without changing admission rates.
•	Use of the test in conjunction with clinical practice performed better than 
clinical practice alone.
•	There was a trend towards reduction of time to diagnosis of preeclampsia 
when using the test.
Summary
The first clinical trial on the use of sFlt-1/PlGF ratio in patients with 
suspected preeclampsia showed that use of the ratio in conjunction 
with standard clinical practice significantly improves clinical preci-
sion without changing admission rates.
Novelty and Significance
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